JP2024523885A5 - - Google Patents
Info
- Publication number
- JP2024523885A5 JP2024523885A5 JP2023577514A JP2023577514A JP2024523885A5 JP 2024523885 A5 JP2024523885 A5 JP 2024523885A5 JP 2023577514 A JP2023577514 A JP 2023577514A JP 2023577514 A JP2023577514 A JP 2023577514A JP 2024523885 A5 JP2024523885 A5 JP 2024523885A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- her3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/099998 | 2021-06-15 | ||
| CN2021099998 | 2021-06-15 | ||
| PCT/CN2022/098929 WO2022262772A1 (en) | 2021-06-15 | 2022-06-15 | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523885A JP2024523885A (ja) | 2024-07-02 |
| JP2024523885A5 true JP2024523885A5 (https=) | 2025-06-20 |
Family
ID=84526843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577514A Pending JP2024523885A (ja) | 2021-06-15 | 2022-06-15 | 抗ｈｅｒ３抗体、それを含有する抗体薬物複合体及びそれらの用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240293565A1 (https=) |
| EP (1) | EP4355787A4 (https=) |
| JP (1) | JP2024523885A (https=) |
| KR (1) | KR20240021294A (https=) |
| CN (1) | CN117500832A (https=) |
| AU (1) | AU2022293634A1 (https=) |
| CA (1) | CA3222478A1 (https=) |
| IL (1) | IL309337A (https=) |
| MX (1) | MX2023015072A (https=) |
| WO (1) | WO2022262772A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202341984A (zh) * | 2022-01-28 | 2023-11-01 | 大陸商映恩生物製藥（蘇州）有限公司 | Ｈｅｒ３抗體藥物偶聯物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1283053A1 (en) * | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| KR101598229B1 (ko) * | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| EA201200195A1 (ru) * | 2009-08-21 | 2012-12-28 | Мерримаск Фармасьютикалс, Инк. | АНТИТЕЛА ПРОТИВ ЭКТОДОМЕНА ErbB3 И ИХ ПРИМЕНЕНИЕ |
| AU2011290672B2 (en) * | 2010-08-20 | 2015-07-09 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (HER3) |
| CA2813796C (en) * | 2010-10-18 | 2019-01-15 | Mediapharma S.R.L. | Erbb3 binding antibody |
| AU2012335543C1 (en) * | 2011-11-09 | 2017-12-14 | Beijing Cotimes Biotech Co., Ltd., | HER3 antibodies and uses thereof |
| CN105367657B (zh) * | 2014-08-14 | 2019-09-13 | 上海生物制品研究所有限责任公司 | 抗her3抗体、其制法及其应用 |
| EP3091033A1 (en) * | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
| EP3176183A1 (en) * | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN117982673A (zh) * | 2017-02-28 | 2024-05-07 | 第一三共株式会社 | 抗her3抗体-药物偶联物的应用 |
-
2022
- 2022-06-15 AU AU2022293634A patent/AU2022293634A1/en active Pending
- 2022-06-15 MX MX2023015072A patent/MX2023015072A/es unknown
- 2022-06-15 CA CA3222478A patent/CA3222478A1/en active Pending
- 2022-06-15 US US18/570,403 patent/US20240293565A1/en active Pending
- 2022-06-15 CN CN202280043063.8A patent/CN117500832A/zh active Pending
- 2022-06-15 WO PCT/CN2022/098929 patent/WO2022262772A1/en not_active Ceased
- 2022-06-15 KR KR1020247001430A patent/KR20240021294A/ko active Pending
- 2022-06-15 JP JP2023577514A patent/JP2024523885A/ja active Pending
- 2022-06-15 EP EP22824247.5A patent/EP4355787A4/en active Pending
- 2022-06-15 IL IL309337A patent/IL309337A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104936617B (zh) | Cd33抗体及其在治疗癌症中的用途 | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| JP2023522229A5 (https=) | ||
| US20230073692A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| JP2020513791A5 (https=) | ||
| JP2012522513A5 (https=) | ||
| JP2017535246A5 (https=) | ||
| JP2018524349A5 (https=) | ||
| US11851460B2 (en) | PD1 binding agents | |
| JP2017512765A5 (https=) | ||
| JP2017518040A5 (https=) | ||
| CA3092174A1 (en) | Pd1 binding agents | |
| WO2015094900A1 (en) | Compounds to fibroblast growth factor receptor-3 (fgfr3) and therapeutic uses | |
| JP2018538368A (ja) | 抗５ｔ４抗体および抗体−薬物コンジュゲート | |
| JP2023509214A5 (https=) | ||
| CN118076387A (zh) | 靶向表达cdh17的肿瘤的多特异性抗体及其制备和使用方法 | |
| JP2023549316A5 (https=) | ||
| CN110678753A (zh) | 用于治疗肺癌的组合物和方法 | |
| JP2023509215A5 (https=) | ||
| JP2024523885A5 (https=) | ||
| JP2025513745A5 (https=) | ||
| JP2025130076A5 (https=) | ||
| JP2022548881A5 (https=) | ||
| IL309337A (en) | Anti-HER3 antibody, anti-HER3 antibody-drug conjugate and uses thereof |